Table 2 Participant demographics and clinical findings of the subgroups
From: Development and clinical validation of CT-based regional modified Centiloid method for amyloid PET
|  | G(−)R(−) | G(−)R(+) | G(+)Str(−) | G(+)Str(+) |
|---|---|---|---|---|
N | 815 | 243 | 85 | 1102 |
Age (years) | 68.1±11.7 | 70.7±9.4 | 73.7±7.2 | 70.1±9.3 |
Gender (F) (N, %) | 437 (53.6) | 128 (52.7) | 60 (70.6) | 635 (57.6) |
APOE4 carriers (N, %) | 110 (14.1) | 69 (29.4) | 28 (34.6) | 636 (59.1) |
SVLT delayed recall, mean ± SD | 5±3.2 | 3.8±3.1 | 3.4±3.4 | 1.4±2.2 |
MMSE, mean ± SD | 27±3.5 | 25.9±4.5 | 25.4±4.5 | 22.3±5.5 |
CDR-SOB, mean ± SD | 1.5±2 | 2±3 | 2.4±3 | 3.9±3.2 |
NC/aMCI/ADD, N | 414/318/83 | 95/115/33 | 26/38/21 | 92/462/548 |
FBB/FMM, N | 331/484 | 95/148 | 41/44 | 575/527 |